Skinmed最新文献

Judging whether an editor is good at the job is essential; however, this task may be difficult or even impossible. Several factors are involved, many of which are beyond the control of an editor. We examined some of such situations, which are as follows: (1) Reviewer's abuse of privileged information, in which a reviewer or an associate, who is likely to be a competitor, directs members of their laboratory to rapidly replicate the data and submit the resulting paper in the same or another journal while delaying publication of the submitted paper; (2) defective micromanagement by a stakeholder or owner, such as failure to order paper for the publication of a journal; (3) penny-wise dollar-foolish mismanagement by the owner, such as limiting the figures allowed to an absurdly low number in a dermatology journal (we have a visual specialty); (4) factional abuse, such as when members of a society use a gimmick to exercise outsized influence to effect a change in journal's content, and (5) "sto tavo (who is in charge)?," in which changes in the governance of an ownership society or publisher affect quality of the journal.

This study focuses on how skincare professionals, such as dermatologists, plastic surgeons, and dermal clinicians, can apply strategies in publishing credible social media content related to the skin. The study interviewed 10 participants and asked questions about the skincare advice they seek from social media. Analysis of the results revealed the prominent themes of education, delivery of information, credibility, trustworthiness, and relatability; however, visual characteristics of how the information was presented, formed the most significant theme. The risk of the public following advice from nonprofessionals on social media includes miscommunication of ideas and adverse reactions that could result in undesirable outcomes; hence, skincare professionals should include correct advice while producing social media content.

A 24-year-old man with no personal or family history of atopic dermatitis or psoriasis consulted our dermatology department with a desquamating reddish lesion on the left areola and nipple. The lesion, which had developed during the past 4 months, bled occasionally and was treated initially as dermatitis with a combination of topical corticoids and antimicrobials, resulting in partial lessening of the condition. An ultrasound of the skin revealed increased blood flow within the nipple thickening of the dermis. During physical examination, we observed a well-defined desquamating plaque with a slightly shiny surface on the left nipple and areola (Figure 1).

BIMZELX^® (bimekizumab-bkzx) injection, for subcutaneous use, was approved in October 2023 for moderate to severe plaque psoriasis in patients aged ≥18 years. In three phase 3, randomized, double-blind, vehicle, and comparator-controlled studies (Be Vivid, Be Ready, and Be Sure), bimekizumab was investigated for the treatment of plaque psoriasis. The primary efficacy end point was psoriatic area and severity index (PASI) 90 (patients with 90% improvement in PASI from baseline) and investigator's global assessment (IGA) score of 0 (clear skin)-1 (almost clear skin) as well as ≥2-point improvement from baseline at week 16. In the Be Vivid study, patients were randomized into the bimekizumab, placebo, and ustekinumab groups. PASI 90 score was achieved by 85% (273/321) in the bimekizumab group, 5% (4/83) in the placebo group, and 50% (81/163) in the ustekinumab group. IGA 0/1 score was achieved by 84% (270/321) in the bimekizumab group, 5% (4/83) in the placebo group, and 53% (87/163) in the ustekinumab group. In the Be Ready study, patients were randomized into bimekizumab and placebo groups. PASI 90 score was achieved by 91% (317/349) in the bimekizumab group and 1% (1/86) in the placebo group. IGA 0/1 score was achieved by 93% (323/349) in the bimekizumab group and 1% (1/86) in the placebo group. In the Be Sure study, patients were randomized into two bimekizumab groups (receiving different bimekizumab regimens) and one adalimumab group. PASI 90 score was achieved by 86.2% (275/319) in combined bimekizumab groups and 47.2% (75/159) in the adalimumab group. IGA 0/1 score was achieved by 85.3% (272/319) in combined bimekizumab groups and 57.2% (91/159) in the adalimumab group. Bimekizumab was well tolerated with no unexpected safety findings.

Pigmented Bowen's disease (pBD) or pigmented squamous cell cancer in situ is uncommon, accounting for 1.67%-5.5% of Bowen's disease lesions. It resembles pigmented actinic keratosis, seborrheic keratosis, solar lentigo, atypical nevus, or melanoma, and is ruled out through biopsy. Pigmented Bowen's disease typically presents as an asymptomatic, flat or slightly raised, scaly, and well-delineated plaque that primarily affects individuals in their sixties. Risk factors include human papilloma virus infection, arsenic exposure, sun exposure, ionizing radiation, and trauma.

Mucormycosis is an invasive fungal infection caused by fungi of the order Mucorales. During the coronavirus disease 2019 (COVID-19), a rise in the number of COVID-19-associated mucormycosis (CAM) patients was reported globally. Cutaneous mucormycosis is the third most common presentation of mucormycosis. It is classified as primary cutaneous and secondary cutaneous mucormycosis. The secondary form is more common than the primary cutaneous; however, most reports and case series in the literature are that of primary cutaneous mucormycosis. We accounted a case series of eight patients of CAM with secondary cutaneous mucormycosis.